Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With SH2D1A/XIAP Hypomorphic Gene Variants

被引:17
|
作者
Ishimura, Masataka [1 ]
Eguchi, Katsuhide [1 ]
Shiraishi, Akira [1 ]
Sonoda, Motoshi [1 ]
Azuma, Yoshihiro [2 ]
Yamamoto, Hiroyuki [1 ]
Imadome, Ken-ichi [3 ]
Ohga, Shouichi [1 ]
机构
[1] Kyushu Univ, Dept Pediat, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan
[2] Yamaguchi Univ, Dept Pediat, Ube, Yamaguchi, Japan
[3] Natl Res Inst Child Hlth & Dev, Div Adv Med Virus Infect, Tokyo, Japan
来源
FRONTIERS IN PEDIATRICS | 2019年 / 7卷
关键词
Epstein-Barr virus; chronic active EBV infection; lymphoproliferative disease; hemophagocytic lymphohistiocytosis; SAP; XIAP; X-linked lymphoproliferative disease; INFECTION; CLASSIFICATION; DEFICIENCY; MUTATIONS;
D O I
10.3389/fped.2019.00183
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
X-linked lymphoproliferative disease (XLP) is one of the X-linked primary immunodeficiency diseases (PIDs) with defective immune response to Epstein-Barr virus (EBV) infection. Chronic active EBV infection (CAEBV) and EBV-hemophagocytic lymphohistiocytosis (HLH) are recognized as systemic EBV-positive T-cell and natural killer (NK)-cell lymphoproliferative diseases (LPDs) arising from the clonal proliferations of EBV-infected T cells and NK cells. A high incidence of CAEBV in East Asia implies the unknown genetic predisposition. In patients with XLP, EBV-infected cells are generally B cells. No mutation of SH2D1A/XIAP genes has ever been identified in patients with systemic EBV-positive T-cell and NK-cell LPD. We report herewith a male case of NK-cell type CAEBV with SH2D1A hypomorphic mutation (c.7G > T, p.Ala3Ser), two male cases of CAEBV/EBV-HLH with XIAP hypomorphic variant (c.1045_1047delGAG, p.Glu349del), and another female case of CD4(+)CAEBV with the same XIAP variant. The female underwent bone marrow transplantation from an HLA-matched sister with the XIAP variant and obtained a complete donor chimerism and a cure of laryngeal LPD lesion, but then suffered from donor-derived CD4(+) T cell EBV-LPD. These observations demonstrated that SH2D1A and XIAP genes are critical for the complete regulation of EBV-positive T/NK cell LPD. X-linked lymphoproliferative disease (XLP) is one of the X-linked primary immunodeficiency diseases (PIDs) reported to have a defective immune response to Epstein-Barr virus (EBV) infection. Mutations in SH2D1A and XIAP genes cause XLP. Systemic EBV-positive T-cell and natural killer (NK)-cell lymphoproliferative diseases (LPDs) consist of three major types: EBV-positive hemophagocytic lymphohistiocytosis (HLH), chronic active EBV infection (CAEBV), and EBV-positive T-cell/NK-cell lymphoma. CAEBV is recognized as a poor prognostic disease of EBV-associated T-cell and NK-cell LPD arising from the clonal proliferation of EBV-infected T cells (CD4(+), CD8(+), and TCR gamma delta(+)) and/or NK cells. The majority of cases with CAEBV were reported from East Asia and South America. In Caucasian patients with CAEBV disease, the target of infection is exclusively B cells. These imply a genetic predisposition to EBV-positive T/NK cell LPD according to ethnicity. In reported cases with XLP, EBV-infected cells are B cells. On the other hand, no mutation of SH2D1A/XIAP genes have been determined in patients with T/NK-cell-type (Asian type) CAEBV. We here describe, for the first time, four case series of CAEBV/EBV-HLH patients who carried the hypomorphic variants of XLP-related genes. These cases included a male patient with CAEBV carrying SH2D1A hypomorphic mutation (c.7G > T, p.Ala3Ser) and two male patients with CAEBV/EBV-HLH carrying the XIAP hypomorphic variant (c.1045_1047delGAG, p.Glu349del), along with another female patient with CAEBV carrying the same XIAP variant. The female case underwent bone marrow transplantation from a healthy HLA-matched sister having the same XIAP variant. Although a complete donor chimerism was achieved with the resolution of laryngeal LPD lesions, systemic donor-derived CD4(+) T-cell EBV-LPD developed during the control phase of intractable graft-vs. - host-disease. These observations demonstrated that SH2D1A and XIAP genes are critical for the complete regulation of systemic EBV-positive T/NK-cell LPD.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders
    Sawada, Akihisa
    Inoue, Masami
    FRONTIERS IN PEDIATRICS, 2018, 6
  • [42] Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma
    Nagamine, Masayoshi
    Takahara, Miki
    Kishibe, Kan
    Nagato, Toshihiro
    Ishii, Hideyuki
    Bandoh, Nobuyuki
    Ogino, Takeshi
    Harabuchi, Yasuaki
    VIRUS GENES, 2007, 34 (01) : 47 - 54
  • [43] Systemic Epstein-Barr virus-positive T-cell lymphoma of childhood treated with the ICE regimen and allogeneic hematopoietic stem-cell transplantation
    Nagahama, Jun
    Nishikawa, Takuro
    Tasaki, Takashi
    Yasudome, Yuki
    Nakamura, Tatsuro
    Abematsu, Takanari
    Nakagawa, Shunsuke
    Kodama, Yuichi
    Tanimoto, Akihide
    Okamoto, Yasuhiro
    PEDIATRIC BLOOD & CANCER, 2023, 70 (03)
  • [44] Association of SH2 domain-containing protein 1A, immunoglobulins and T lymphocyte subsets with Epstein-Barr virus infections
    Xu, Penghong
    Zhou, Jinsu
    Xiao, Yue
    Miao, Hongjun
    TURKISH JOURNAL OF PEDIATRICS, 2023, 65 (04) : 603 - 610
  • [45] The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation
    Jeon, Y. K.
    Park, C. H.
    Kim, K-Y
    Li, Y. C.
    Kim, J.
    Kim, Y. A.
    Paik, J-H
    Park, B-K
    Kim, C-W
    Kim, Y-N
    JOURNAL OF PATHOLOGY, 2007, 213 (02) : 170 - 179
  • [46] TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients
    Cho, Junhun
    Kim, Eojin
    Yoon, Sang Eun
    Kim, Seok Jin
    Kim, Won Seog
    CANCER, 2023, 129 (10) : 1502 - 1512
  • [47] PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial
    Sun, Yu-Ting
    Guan, Wen-Long
    Zhao, Qi
    Wang, De-Shen
    Lu, Shi-Xun
    He, Cai-Yun
    Chen, Shuang-Zhen
    Wang, Feng-Hua
    Li, Yu-Hong
    Zhou, Zhi-Wei
    Xu, Rui-Hua
    Qiu, Miao-Zhen
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (10): : 5006 - +
  • [48] Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma
    Gahn, B
    Siller-Lopez, F
    Pirooz, AD
    Yvon, E
    Gottschalk, S
    Longnecker, R
    Brenner, MK
    Heslop, HE
    Aguilar-Cordova, E
    Rooney, CM
    INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (05) : 706 - 713
  • [49] Selected amino acid change encoding Epstein-Barr virus-specific T cell epitope of the LMP2A gene in Japanese nasal NK/T cell lymphoma patients
    Nagamine, Masayoshi
    Kishibe, Kan
    Takahara, Miki
    Nagato, Toshihiro
    Ishii, Hideyuki
    Bandoh, Nobuyuki
    Ogino, Takeshi
    Harabuchi, Yasuaki
    INTERVIROLOGY, 2007, 50 (05) : 319 - 322
  • [50] Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders
    Gao, Li-Min
    Zhao, Sha
    Zhang, Wen-Yan
    Wang, Mi
    Li, Hui-Fang
    Lizaso, Anle
    Liu, Wei-Ping
    CANCER BIOLOGY & THERAPY, 2019, 20 (10) : 1319 - 1327